Summary of Xiansheng Pharmaceutical Conference Call Company Overview - **Company**: Xiansheng Pharmaceutical - **Industry**: Pharmaceutical, focusing on oncology and neurology Key Points Oncology Pipeline Highlights - **Core Products**: - Enze Shou (苏维西西达单抗) has been approved and included in the medical insurance directory, showing clear overall survival (OS) benefits for platinum-resistant ovarian cancer [6] - Kexaila (曲拉西利) is a CDK46 inhibitor, conditionally approved in 2022, expected to enter the medical insurance directory by the end of 2024 [6] - Enlituz (EGFR monoclonal antibody) is also expected to enter the medical insurance directory by the end of 2024 [6] New Product Launches - **Dali Le Sheng**: A new insomnia drug with significant market potential, expected to enhance performance rapidly. It reaches plasma peak in 1-2 hours and has an 8-hour half-life, aligning with human sleep cycles [2][3][7] - **Future Innovations**: Multiple innovative drugs are expected to launch in the coming years, including: - Madunosawe (抗流感), anticipated approval in 2026 [11] - New RSV infection drug, currently in slower clinical progress [11] Research and Development Investments - **R&D Spending**: In the first half of 2025, R&D investment reached 1.03 billion yuan, accounting for approximately 29% of revenue [4] - **Funding**: Raised 1.5 billion HKD through share placement, with 90% allocated for R&D [4] - **BD Collaborations**: Significant partnerships with companies like AbbVie, indicating international recognition of innovation capabilities [5] Market Potential and Competitive Landscape - **Insomnia Market**: The insomnia prevalence in China is 29.2%, with Dali Le Sheng addressing unmet needs in sleep onset and maintenance without next-day drowsiness [7][10] - **Safety Profile**: Dali Le Sheng is classified as a non-controlled substance, indicating a high safety profile and no addiction potential, allowing for broader market access [10] Financial Projections - **Short-term Growth**: Existing products entering the medical insurance directory and new launches like Dali Le Sheng are expected to drive revenue and profit growth [8][14] - **Long-term Outlook**: Continuous R&D investment and a robust pipeline suggest sustained growth momentum, with a target price of 20.16 HKD and a total market value of 48 billion RMB, indicating over 60% upside potential from current prices [4][8] Risks and Challenges - **Market Risks**: Potential risks in the autoimmune sector, particularly with the consistency evaluation of existing products, but new products like Jack One inhibitors are expected to mitigate these risks [15][16] Summary of Current Pipeline Performance - **Core Products**: The existing pipeline is performing well, with significant market share for key products like Xianbixin injection [15] - **Growth Opportunities**: New indications for existing drugs, such as Shisuan Jianjia for post-stroke cognitive impairment, are being explored for additional growth [16]

Core Viewpoint - The construction of a unified national market is a significant decision made by the central government, essential for building a new development pattern and addressing long-term national development strategies [5]. Group 1: Market Construction and Challenges - China, as the world's second-largest consumer market with over 1.4 billion people and more than 190 million business entities, has a substantial advantage in market resources that supports economic growth and innovation [5]. - The establishment of a unified national market has seen positive outcomes, including improved market infrastructure and smoother flow of goods and services, but challenges such as local protectionism and market segmentation remain [7][10]. - Recent measures have been implemented to eliminate market barriers, such as the reduction of the negative list for market access to 106 items, a nearly 30% decrease since 2018 [7]. Group 2: Competition and Quality - The phenomenon of "involution" in competition, characterized by low-price and low-quality practices, has been identified as detrimental to market mechanisms and innovation [8]. - The government has initiated actions to curb "involution" in various industries, including the solar and automotive sectors, emphasizing the importance of quality and standards in fostering healthy competition [8][9]. Group 3: Open Market Strategy - The construction of a unified national market is not a closed system but aims to promote reform and openness, facilitating both domestic and international economic cycles [9]. - The negative list for foreign investment has been reduced to 29 items, with all manufacturing sector restrictions eliminated, indicating a commitment to high-level openness [9]. Group 4: Case Studies - The cross-network electricity trading mechanism has been established, allowing for significant electricity transfers across regions, exemplifying the practical implementation of a unified market [12]. - The flower industry in Yunnan has transitioned from unregulated sales to standardized production, enhancing market access and pricing for quality products [13]. - The rapid introduction of new drugs, such as "Kexaira," into the Chinese market through Hainan's pilot policies demonstrates the effectiveness of streamlined regulatory processes and local production capabilities [15][16].

本期主讲人：习近平经济思想研究中心副主任 李玉举 视频报道请看人民日报客户端、"人民网+"客户端，英文报道请看环球时报英文版客户端 海南先声药业实验室，工作人员在做实验。 人民网记者 皇甫万里摄 云南昆明斗南花卉市场一角。 受访者供图 闽粤联网工程福建云霄换流站。 资料图片 建设全国统一大市场，是以习近平同志为核心的党中央作出的重大决策。这不仅是构建新发展格局的基 础支撑和内在要求，也是关乎国家发展全局和长远的战略之举。 当今世界，市场是最稀缺的资源。作为全球第二大消费市场，中国拥有14亿多人口、超1.9亿户经营主 体，这样超大规模且极具增长潜力的市场，是我国发展的巨大优势和应对变局的坚实依托，对资源集 聚、创新激励、产业升级、经济增长发挥着有力支撑作用。如何用好市场资源和优势？纵深推进全国统 一大市场建设，至关重要。 近年来，我们加强战略谋划和顶层设计，出台关于加快建设全国统一大市场的意见，围绕完善法律规范 或操作指引，制定系列配套措施，推动全国统一大市场建设取得积极成效——市场基础制度不断完善， 市场设施互联互通显著增强，商品服务和资源要素流动更加顺畅，统一大市场的规模效应和集聚效应不 断彰显。但是我们也 ...

国金证券发表研究报告指，首予先声药业"买入"评级，目标价20.16港元。该行表示，先声药业创新转 型成效显著，商业化创新药已增至10款，创新药收入占比从2020年的45%提升至今年上半年的77%。短 期来看，核心管线进入密集收获期，药物获纳入医保目录，有望加速放量；重磅失眠药兼具消费属性， 市场潜力大。长期来看，自研管线聚焦差异化，多款产品已实现BD，创新能力持续得到验证，技术平 台和管线可望持续BD出海。另外，公司稳健成长系列品种持续为其带动稳定的现金流。 ...

Core Viewpoint - The report from Guojin Securities indicates that Xiansheng Pharmaceutical (02096) is expected to experience strong growth due to the resonance of short-term pipeline expansion and long-term innovation iteration, forecasting revenue of 7.63 billion, 9.10 billion, and 11.04 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth of +15.0%, +19.3%, and +21.4% [1] Group 1 - The company has significantly improved its innovation transformation, with the revenue share of innovative drugs rising to 77% by the first half of 2025, up from 45% in 2020 [2] - The company focuses on four core therapeutic areas: neurology, oncology, autoimmune diseases, and anti-infection, leveraging a dual approach of self-research and business development [2] Group 2 - In the short term, the core pipeline is entering a concentrated harvest period, with accelerated inclusion in medical insurance expected to boost performance; key products in oncology and neurology are anticipated to see rapid market release [3] - The insomnia drug Dali Leisheng, which has a fast onset and non-addictive properties, is expected to have significant market potential due to its consumer attributes [3] Group 3 - In the long term, the self-research pipeline focuses on differentiated targets, with several products already achieving business development; the innovative capabilities of the company continue to be validated [4] - The NMTiADC new technology platform is expected to overcome ADC resistance, with related products entering clinical trials to accelerate the validation of platform strength [4]

Core Viewpoint - The Chinese innovative pharmaceutical industry is experiencing a surge in business development (BD) transactions, but the secondary market's reaction has been mixed, with many companies seeing stock price declines despite positive announcements [2][6][10]. Group 1: Recent BD Transactions - Numerous BD transactions have been announced recently, including partnerships between Jiangsu Zaiming and Ipsen, and between Akeso and AstraZeneca, among others [2]. - In 2023, over 100 license-out transactions were completed in China, totaling more than $110 billion [4]. - As of December 21, 2025, there have been 15 transactions with upfront payments exceeding $100 million, and 37 transactions with total amounts over $1 billion, ranking second only to the U.S. [5]. Group 2: Market Reactions - Following the announcement of BD transactions, stock prices have shown varied responses; for instance, Akeso's stock fell by 13.58% on December 22, while Qianxin Bio's stock rose by 1.44% on the same day [3][6]. - A total of 37 BD transactions in A-shares and Hong Kong stocks this year resulted in 21 instances of stock price increases and 15 instances of declines on the first trading day after the announcements [6]. - The overall sentiment in the market has shifted from enthusiasm to a more rational approach, with stock prices reflecting this change [8][10]. Group 3: Industry Insights - Industry experts suggest that the complexity and long-term nature of innovative drug development require a rational approach from both capital and product markets [6][10]. - The current trend indicates that many Chinese pharmaceutical companies are still reliant on the "borrowed boat" strategy for international expansion, with a focus on licensing out rather than direct commercialization [12][13]. - The choice of out-licensing models varies, with smaller companies typically opting for complete licensing, while larger firms are exploring co-development models to retain longer-term benefits [13][14].

全球化布局与产业链协同进一步拓宽了企业韧性发展的边界。先声药业加速推进国际化进程，2025年，旗下先声再明与艾伯维、NextCure、益普生陆续达成 3项自研产品出海合作，潜在总交易金额超29亿美元，累计实现4项自研出海，创新能力获得国际一流企业认可。同时，通过提升研发BD组织能力、整合外 部资源推进开放式创新，让研发投入和收入增长进入良性循环，强化了产业链协同效能。 "金智奖"旨在树立高质量发展标杆，引导上市公司聚焦主业、持续创新、践行社会责任，推动资本向优质企业集聚。本届评选中，金融界上市公司研究院紧 密契合"十五五"规划建议中"提升上市公司质量"的要求，将高质量发展内核分解为社会责任、实业贡献、投资回报、成长前景、创新效率、杰出品牌六大维 度，以企业财务数据和公开信息为基础建立量化分析模型，最终覆盖A股、港股及中概股超8000家企业，评选出近200家获奖企业。 在复杂多变的市场环境中，上市公司的"韧性"已超越传统财务稳健的范畴，成为衡量企业长期价值与可持续发展能力的核心标尺。"上市公司韧性发展"聚焦 企业战略适配性、核心业务抗风险水平、产业链协同效能、创新驱动实力、ESG践行深度等水平。旨在推动企业高质 ...

Core Viewpoint - The company has entered a significant phase of monetization with its innovative drug pipeline, as evidenced by the recent licensing agreement for SIM0613 with Ipsen for $45 million upfront and a total of $1.06 billion, indicating a trend towards external licensing of its products [1][2]. Group 1: Product Development and Licensing - The licensing of SIM0613 marks the company's third external authorization project in 2025, confirming the advancement of its innovative drug pipeline [1]. - SIM0613 has shown advantages in preclinical models, particularly in osteosarcoma and triple-negative breast cancer, positioning it as a potential first-in-class (FIC) therapy globally [2]. - The ADC platform's capabilities are further validated with the second transaction involving SIM0613, following SIM0505, which is currently in Phase I clinical trials [2]. Group 2: Global Pipeline Expansion - The company is accelerating its global pipeline expansion, with multiple products and technology platforms poised for overseas exploration, including SIM0709, a dual antibody with significant global competitiveness [2]. - Clinical results for SIM0237 have been disclosed, showing promising outcomes in bladder cancer patients, indicating the potential for further development [2]. - The company is rapidly advancing its global clinical trials, with SIM0500 in Phase I and SIM0278 in Phase II, demonstrating effective collaboration with partners [2]. Group 3: New Product Contributions to Growth - New products are becoming a strong driver for future growth, particularly in the CNS field with the launch of a non-addictive insomnia treatment, which has quickly gained traction since its release [3]. - The oncology sector is also benefiting from the potential of oral SERDs, with ongoing Phase III trials validating the market opportunity [3]. - In the infection and autoimmune sectors, new products are expected to receive regulatory approval by 2026, further enhancing the company's growth prospects [3]. Group 4: Financial Projections and Valuation - The company maintains its adjusted net profit forecasts for 2025-2027 at 1.18 billion, 1.40 billion, and 1.52 billion yuan, respectively, with a CAGR of 14% [3]. - The target price has been adjusted to 19.82 HKD based on a PE valuation method, reflecting a shift in market expectations for comparable companies [3].

Core Viewpoint - The recent "Technology Empowerment · Capital Breakthrough" sharing session by Gelonghui revealed the annual list of outstanding companies, highlighting the recognition of excellence in the biopharmaceutical sector [1] Group 1: Company Recognition - Ascletis Pharma (2096.HK) was awarded the "Annual Outstanding Biopharmaceutical Company" at the Gelonghui "Golden G Award" annual selection [1] - The award evaluates companies based on multiple factors including technological innovation, research and development strength, and the ability to translate research outcomes into clinical or commercial applications [1]

Major Events - Kuaishou-W (01024) strongly condemns illegal activities related to black and gray industries, has reported to law enforcement and relevant authorities [1] - Sihon Pharmaceutical (02096) receives clinical trial approval for SIM0610 (EGFR/cMET bispecific antibody-drug conjugate) from the National Medical Products Administration [1] - Sinopec Engineering (02386) plans to acquire 100% equity of East China Pipeline Design Institute [1] - Yanda Pharmaceutical (00512) introduces the world's first epinephrine nasal spray for treating severe allergic reactions [1] - Valiant Pharmaceuticals-B (09887) reports the first subject has been dosed in Phase I trial of LBL-047 [1] - Xinyi Energy (03868) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for 62 million yuan [1] - Zhongneng Holdings (00228) plans to receive a premium of approximately 9.03% for a full acquisition offer, with resumption of trading on December 24 [1] Operating Performance - Xipuni (02583) issues a profit warning, expecting annual net profit to increase year-on-year [1] - AEON CREDIT (00900) reports a profit of 353 million HKD for the first three quarters, an increase of 28.11% year-on-year [1] - New Fire Technology Holdings (01611) anticipates an annual net loss not exceeding 10 million HKD [1]